An ANGPTL4 inhibitory antibody safely improves lipid profiles in non-human primatesResearch in context

Summary: Background: Angiopoietin-like protein 4 (ANGPTL4) inhibition is a promising approach to manage atherogenic dyslipidaemia and residual atherosclerotic cardiovascular disease (ASCVD) risk. Human ANGPTL4 loss-of-function (LoF) is associated with reduced plasma triglyceride (TG), remnant chole...

Полное описание

Библиографические подробности

Главные авторы:	Beryl B. Cummings, Page R. Bouchard, Mark N. Milton, Peter F. Moesta, Vyas Ramanan, John W. Trauger, Eleftheria Maratos-Flier, Andrei Voznesensky, Igor Splawski, Amitabh V. Nimonkar, Keith DiPetrillo, Daniel LaSala, Meihui Pan, Meghan M. Flaherty, Francois Huet, Sukhdeep K. Sahambi, Jijun Dong, Deborah Knee, Regis Cebe, Thomas Huber, Joshua Lehrer-Graiwer, Rebecca A. Juliano, Ethan J. Weiss
Формат:	Artigo
Язык:	Inglês
Опубликовано:	Elsevier 2025-07-01
Серии:	EBioMedicine
Предметы:	MAR001 ANGPTL4 Triglyceride Remnant cholesterol Non-human primates Safety
Online-ссылка:	http://www.sciencedirect.com/science/article/pii/S2352396425001926
Метки:	Добавить метку Нет меток, Требуется 1-ая метка записи!